Speaker CV

Dr. Nor Hafizah graduated with Medical Degree from Universiti Sains Malaysia in 2004 and Master in Medicine (Transfusion Medicine) from USM in 2013. Her area of interest is Immunohematology(Region Medical Skane University Lund & Clinical Immunology and Transfusion Medicine Office for Medical Services, Lund, Sweden). Patient Blood Management/Clinical Transfusion (Immunology and Transfusion Medicine, Karolinska University Hospital, Huddinge, Stockholm).

Currently she holds the position as Head of Clinical Transfusion Division, Transfusion Medicine Specialist, Institution National Blood Centre, Kuala Lumpur, Malaysia from 2018. Previously, 2013 - 2015 Transfusion Medicine Specialist, National Blood Centre, Malaysia. 2016 - 2017 Head of Immunohematology Division, National Blood Centre Malaysia.

NATIONAL & INTERNATIONAL MEMBERSHIPS/ACTIVITIES:

1. Committee Member of the Malaysian Blood Transfusion Society (2018 -2021)
2. Life Member of the Malaysian Blood Transfusion Society
3. Member of the International Society for Blood Transfusion (ISBT)
4. Member of Society of Advancement in Blood Transfusion (Student-Resident) 2020-
5. 2022
6. Participant of I TRY IT ISBT Program (2020)
7. Participant of Young Professional Peer Review ISBT 2021
8. Local Organizing Committee International Society for Blood
9. Transfusion (ISBT) Kuala Lumpur 2013
10. Local Organizing Committee ISBT Kuala Lumpur 2022
11. Transfusion Evidence Round-Up ISBT (Reviewer) ‘World Cancer Day’ 4th Feb 2022
12. 75th Session Of The World Health Assembly Geneva, Switzerland
13. 22 – 28 MAY 2022-Preparing Intervention Notes on Availability, safety and quality of
14. blood Products for 75th Session Of The World Health Assembly Geneva, Switzerland
15. Member of Working Party of Rare Donor ISBT Working Party (2022 till current)

RESEARCH ACTIVITIES:

1. 2018-current: An open-labelsingle-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of N8-GP in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A ( Sub Investigator)
2. 2018 - current: An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously untreated patients with haemophilia B (FIX activitiy< 2%) ( Sub Investigator)
3. 2018 - current: A Phase III open label, Multicentre Extension Study to Assess the Safety & Efficacy of Recombinat Coagulation Factor VIII (rVIII-SingleChain, CSL627) In Subjects with Severe Hemophilia A
4. 2013: Usage of Fresh Frozen Plasma (FFP) in Hospital Kuala Lumpur
5. 2021: Hemoglobin level during pregnancy and the associated outcome in maternity patients.
6. 2022: Enzymatic Processing of O Rh(D) negative blood to produce rare Bombay blood for transfusion to rare Bombay patients (Collaboration research with researchers from Karolinska Institute, Stockholm)

COMMITTEES SERVED WITHIN MINISTRY OF HEALTH, MALAYSIA:

1. 2016 Contributor for Transfusion Practice guidelines for clinician and laboratory personnel 4th edition 2016
2. 2020 Editors Handbook on Clinical Use of Blood 3rd Edition 2020
3. 2020 Committee Clinical Practice Guideline Dengue In Children 2020
4. 2013- current Hospital Transfusion Committee, PDN/HKL
5. 2020 Clinical Practice Guidelines (CGP) on Management of Dengue in Children
6. 2021 Malaysian Patient Safety Goal 2.0 (Guidelines On Implementation Surveillance) (Contributors)
7. 12 November 2020 Guideline For Collection, Processing & Use of Convalescent Plasma (CP) for Experimental Treatment of Covid-19 (Annex 43 Covid-19 Malaysia) 12 November 2020
8. 2013 -current Member of Hospital Transfusion Committee, Hospital Kuala Lumpur & Hospital Tengku Azizah
9. 2020 Guidelines On Transfusion Practice During Covid-19 Pandemic (Contributor)
10. 2022 Contributor Guideline on Disaster Plan Transfusion Service